Peptilogics is a clinical-stage biotechnology company that designs and develops novel peptide therapeutics. Through their computational platform, Peptilogics is radically altering drug discovery by not only uncovering new, previously unexplored chemical design space, but ensuring that each potential therapeutic is biologically viable and scalable to manufacture. Peptilogics' lead clinical stage peptide therapeutic, PLG0206, is a novel, broad-spectrum anti-infective that has been granted FDA Orphan Drug Designation and Qualified Infectious Disease Product Designation for its initial focus on the treatment of prosthetic joint infections, an unmet medical need.

Biotechnology

Peptilogics

Jonathan Steckbeck

Marc Lesnick

Albert Fonticiella

Steve Kulp

Atul Deshpande Ph.d.

David Huang

Bradd Picone

Nicholas Pachuda

Nick Nystrom

The executive team at Peptilogics has a history of working in the medical field and with various companies, including HARVEST FOR THE HUNGRY INC, Motif Bio, ContraFect Corp, Rutgers New Jersey Medical School, EPAM Systems, Elucidata Corporation, Wyss Institute for Biologically Inspired Engineering, and Massachusetts Institute of Technology. They also have a wide range of educational backgrounds, including epidemiology, medicine, and microbial biochemistry.

CEO and Executive Team

Leadership Team

Board of Directors

CEO and Executive Team

About

Team members

Other teams at Peptilogics

Leadership Team

Board of Directors